Pyxis Oncology (PYXS) Operating Income (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Operating Income of -$18.3 million for Q4 2025, up 54.34% year-over-year from -$11.9 million in Q4 2024, and up 22.02% quarter-over-quarter from -$23.5 million in Q3 2025.
Pyxis Oncology (PYXS) Operating Income (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Operating Income for 6 consecutive years, with -$18.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Income rose 54.34% year-over-year to -$18.3 million; the TTM figure through Dec 2025 stood at -$84.4 million (up 5.63% YoY), while the FY2025 annual figure was -$84.4 million, up 5.63% from the prior year.
- Operating Income grew to -$18.3 million in Q4 2025 per PYXS's latest filing, from -$23.5 million in the prior quarter.
- Across five years, Operating Income topped out at -$5.6 million in Q1 2024 and bottomed at -$40.1 million in Q4 2024.
- Historically, Operating Income has averaged -$22.5 million across 5 years, with a median of -$21.9 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Income tumbled 333.02% — and 2024, when it jumped 73.25%.
- Pyxis Oncology's Operating Income stood at -$16.4 million in 2021, then plunged by 131.18% to -$38.0 million in 2022, then jumped by 53.21% to -$17.8 million in 2023, then plunged by 125.52% to -$40.1 million in 2024, then jumped by 54.34% to -$18.3 million in 2025.
- Business Quant data shows PYXS's Operating Income at -$18.3 million in Q4 2025, -$23.5 million in Q3 2025, and -$19.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | -25.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.99 Mn |
| Dec 31, 2025 | -18.30 Mn |
| Sep 30, 2025 | -23.46 Mn |
| Jun 30, 2025 | -19.75 Mn |
| Mar 31, 2025 | -22.91 Mn |
| Dec 31, 2024 | -40.07 Mn |
| Sep 30, 2024 | -23.75 Mn |
| Jun 30, 2024 | -20.03 Mn |
| Mar 31, 2024 | -5.61 Mn |
| Dec 31, 2023 | -17.77 Mn |
| Sep 30, 2023 | -25.35 Mn |
| Jun 30, 2023 | -18.12 Mn |
| Mar 31, 2023 | -20.95 Mn |
| Dec 31, 2022 | -37.97 Mn |
| Sep 30, 2022 | -28.39 Mn |
| Jun 30, 2022 | -25.73 Mn |
| Mar 31, 2022 | -31.39 Mn |
| Dec 31, 2021 | -16.43 Mn |
| Sep 30, 2021 | -11.62 Mn |
| Jun 30, 2021 | -5.94 Mn |